Article Details

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for ...

Retrieved on: 2023-01-08 23:51:13

Tags for this article:

Click the tags to see associated articles and topics

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for .... View article details on hiswai:

Excerpt

At the data cutoff date on Dec 23, 2021, the ORR by BICR was 83.7% ... All statistical analyses were performed using SAS® Version 9.3 or higher.

Article found on: bmcmedicine.biomedcentral.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up